Term ends Apr 17, 2039 · Low confidence

Computed 20-year base term

Filed Oct 14, 2020 as application 17/070,554 · Granted Oct 18, 2022

USPTO first gave this application the number US 11,440,897 and withdrew it before it issued. That number now leads here.

Base term, 20 years from filing

Today

20 years from filing

Term ends Apr 17, 2039

2019 2039

Clock starts
Apr 17, 2019

Term ends
Apr 17, 2039

Granted
Oct 18, 2022

base term fee events Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

None

Term adjustment

No prosecution delay on this record.

No effect

Terminal disclaimer

Resolved from the filed document, referencing US 10,968,201, to Apr 17, 2039. The term already ends on or before that date, so the cap shortened nothing.

1 of 3

Maintenance fees paid

Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.

Family applications on record here

Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: Low. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.

Step	Input	Date after this step	Confidence
Base term, 20 years from filing	Clock starts Apr 17, 2019, when application 16/387,294, the earliest non-provisional in its chain, was filed (this one was filed Oct 14, 2020); a parent in its chain could not be resolved (the next row)	Apr 17, 2039	High confidence
Continuity chain	A parent in the chain could not be resolved	dated from this application's own claim	Medium confidence
Patent term adjustment	None on file	no change	High confidence
Terminal disclaimer cap	Disclaimer resolved from the filed document (refs US 10,968,201)	resolves to Apr 17, 2039, no earlier than this term, so no change	High confidence
Patent term extension	None on file	no change	High confidence
Fee events	1 of 3 maintenance fees paid	In force	High confidence
Further caveats on record	The record names parents not resolved: 16387294	Low confidence overall	Low confidence
Computed term end	The steps above, in order	Apr 17, 2039	Low confidence

This family

US 10,968,201	In force Apr 2039	Apr 2039
US 11,472,789	this patent Apr 2039	Apr 2039
US 11,795,156	In force Apr 2039	Apr 2039
US 12,215,093	In force Apr 2039	Apr 2039
Application 18/988,376	Pending not computed	not computed

The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.

Recorded	Assignor	Assignee	Conveyance
Oct 14, 2020 Reel 54172, frame 671	Ding, Jinyue; Gomez, Robert; Lam, Heather; Oballa, Renata Marcella; Powell, David Andrew; Sheng, Tao	Inception Sciences Canada, Inc.	Assignment of Assignor's Interest
Oct 14, 2020 Reel 54332, frame 550	Inception Sciences, Inc.; Inception Sciences Canada, Inc.	Tempest Therapeutics, Inc.	Assignment of Assignor's Interest
Oct 14, 2020 Reel 54406, frame 573	Bravo, Yalda; Chen, Austin Chih-yu; Nagamizo, Joe Fred	Inception Sciences, Inc.	Assignment of Assignor's Interest
Mar 15, 2021 Reel 55599, frame 368	Inception Sciences, Inc.; Inception Sciences Canada, Inc.	Tempest Therapeutics, Inc.	Corrective Assignment to Correct the Execution Date Previously Recorded at Reel: 054332 Frame: 0550. Assignor(S) Hereby Confirms the Correct Execution Adate of Assignor.
Dec 28, 2022 Reel 62221, frame 808	Tempesttx, Inc. (F/K/A Tempest Therapeutics, Inc.); Tempest Therapeutics, Inc. (F/K/A Millendo Therapeutics, Inc.); Millendo Therapeutics US, Inc.	Oxford Finance LLC	Security Interest
Apr 10, 2025 Reel 70806, frame 566	Oxford Finance LLC	Tempesttx, Inc.; Tempest Therapeutics, Inc.; Millendo Therapeutics US, Inc.	Release of Security Interest
Apr 10, 2025 reel/frame not recorded	Oxford Finance LLC	Tempesttx, Inc.	Release of Security Interest
Apr 10, 2025 reel/frame not recorded	Oxford Finance LLC	Tempest Therapeutics, Inc.	Release of Security Interest
Apr 10, 2025 reel/frame not recorded	Oxford Finance LLC	Millendo Therapeutics US, Inc.	Release of Security Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

What's changing

Apr 2039

Term ends Apr 17, 2039. Maintenance fees still fall due before then

Terminal disclaimer

A terminal disclaimer resolved from the filed document, referencing US 10,968,201, ends no earlier than this term, so it caps nothing.

Citations

later US patents cite this one

That is top 25% of utility patents granted in 2022 in our data, the only group it is compared against. How we rank

Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.

Bicyclic Carboxamides and Methods of Use Thereof